AAA has completed a capital increase of €40 million, which will help fund expansion plans and finance clinical trials of its promising portfolio of Radio Metabolic Therapy and diagnostic products.
The fundraising was subscribed by existing and new shareholders, including private investors and pharmaceutical companies. New shareholders include the leading Italian biopharmaceutical company Dompé, which has acquired a 7.7% stake in AAA. Following the capital increase, the number of shareholders in AAA has risen to 116 from 88.
Stefano Buono, CEO of AAA, commented, “We were delighted by the strong support for our latest financing from current and new shareholders. The money raised will help us to accelerate our international growth and finance the development of our promising product pipeline, including Lutathera®. We will also continue to seek complementary acquisitions which will enable us to achieve our goal of making AAA the leading global company in the field of innovative Radio Metabolic Therapy products. We welcome Eugenio Aringhieri to the Board of AAA. His industry insights and his experience of working with pharmaceutical and biotech companies will be of great value to us as we continue to execute our strategy.”